Plasma Exchange in Alzheimer's Disease

Lithography-free interdigitated electrodes by trench-filling patterning on polymer substrate for Alzheimer's disease detection

Microelectrodes have played a crucial role in electrochemistry for the last few decades. However, the conventional lithographic processes, the key players in fabrication, are nonetheless technologically challenging, pricey, and lack reproducibility. In this work has developed a novel and low-cost patterned-replication fabrication technology for interdigitated electrode array (IDA) electrodes on the polymer substrate. Conventional UV-lithography has been utilized to fabricate the nickel IDA electrode pattern as a master mold on the stainless-steel substrate, which was replicated onto the polymer substrate by the hot-emboss technique. Then, gold was deposited on the replicated wafer by electron beam evaporation, and finally adhesive tape lift-off was used to obtain the gold IDA electrode. The fabricated IDA electrode was applied for electrochemical detection of various p-aminophenol (PAP) concentrations as a representative biomarker with a detection limit of 0.01 nM. Finally, different levels of amyloid beta 42 (Aß42) and amyloid beta aggregated (Aß Agg.), two Alzheimer's disease (AD) biomarkers, were measured using the developed IDA electrode via e-ELISA using enzyme by-products PAP. While quantified, the proposed IDA electrode successfully detects Aß42 and Aß Agg. with the lower detection limit (LOD) of 3.9 and 7.81 pg/ml, respectively.

Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

Neurodegenerative disease (ND) incidence has recently increased due to improved life expectancy. Alzheimer's (AD) or Parkinson's disease (PD) are the most prevalent NDs. Both diseases are poly genetic, multifactorial and heterogenous. Preventive medicine, a healthy diet, exercise, and controlling comorbidities may delay the onset. After the diseases are diagnosed, therapy is needed to slow progression. Recent studies show that local, peripheral and age-related inflammation accelerates NDs' onset and progression. Patients with autoimmune disorders like inflammatory bowel disease (IBD) could be at higher risk of developing AD or PD. However, no increase in ND incidence has been reported if the patients are adequately diagnosed and treated. Autoantibodies against abnormal tau, β amyloid and α- synuclein have been encountered in AD and PD and may be protective. This discovery led to the proposal of immune-based therapies for AD and PD involving monoclonal antibodies, immunization/ vaccines, pro-inflammatory cytokine inhibition and anti-inflammatory cytokine addition. All the different approaches have been analysed here. Future perspectives on new therapeutic strategies for both disorders are concisely examined.

Plasma Exchange Reduces Aβ Levels in Plasma and Decreases Amyloid Plaques in the Brain in a Mouse Model of Alzheimer's Disease

Alzheimer's disease (AD) is the most common type of dementia, characterized by the abnormal accumulation of protein aggregates in the brain, known as neurofibrillary tangles and amyloid-β (Aβ) plaques. It is believed that an imbalance between cerebral and peripheral pools of Aβ may play a relevant role in the deposition of Aβ aggregates. Therefore, in this study, we aimed to evaluate the effect of the removal of Aβ from blood plasma on the accumulation of amyloid plaques in the brain. We performed monthly plasma exchange with a 5% mouse albumin solution in the APP/PS1 mouse model from 3 to 7 months old. At the endpoint, total Aβ levels were measured in the plasma, and soluble and insoluble brain fractions were analyzed using ELISA. Brains were also analyzed histologically for amyloid plaque burden, plaque size distributions, and gliosis. Our results showed a reduction in the levels of Aβ in the plasma and insoluble brain fractions. Interestingly, histological analysis showed a reduction in thioflavin-S (ThS) and amyloid immunoreactivity in the cortex and hippocampus, accompanied by a change in the size distribution of amyloid plaques, and a reduction in Iba1-positive cells. Our results provide preclinical evidence supporting the relevance of targeting Aβ in the periphery and reinforcing the potential use of plasma exchange as an alternative non-pharmacological strategy for slowing down AD pathogenesis.